Literature DB >> 16612564

YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.

C N Rathcke1, J S Johansen, H Vestergaard.   

Abstract

OBJECTIVE AND
DESIGN: YKL-40 participates in inflammatory states and vascular processes, which implies that comparison can be made with other inflammatory markers associated with insulin resistance and type 2 diabetes (T2D). In the present study levels of plasma YKL-40 and serum hsCRP were evaluated in patients with T2D.
MATERIALS AND METHODS: Patients with T2D and age-matched healthy controls participated in the study. Insulin resistance was estimated using HOMA-IR model. Biochemical parameters were measured in venous blood after a 10 h fast.
RESULTS: Patients with T2D were insulin resistant (p<0.001) and had raised levels of plasma YKL-40 (p<0.001) and serum hsCRP (p<0.001). YKL-40 was correlated with HOMA-IR (r=0.23, p<0.01), NEFA (r=0.32, p<0.001) and triglycerides (r=0.24, p<0.05). YKL-40 and hsCRP were not correlated (r=0.17, p=NS). All participants with hsCRP<1 mg/l had higher insulin sensitivity (p<0.05 and p<0.01, respectively). HsCRP were predicted by HOMA-IR and BMI (r2=0.48, p<0.01). Plasma YKL-40 was predicted by HOMA-IR and triglycerides (r2=0.27, p<0.01).
CONCLUSIONS: YKL-40 and hsCRP are elevated in patients with T2D and are related to insulin resistance. No correlation was found between YKL-40 and hsCRP indicating that increased levels of YKL-40 occur independently from elevated plasma hsCRP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612564     DOI: 10.1007/s00011-005-0010-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  52 in total

1.  The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.

Authors:  Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup
Journal:  Inflamm Res       Date:  2010-10-23       Impact factor: 4.575

2.  Chitinase-like proteins in lung injury, repair, and metastasis.

Authors:  Chun Geun Lee; Charles S Dela Cruz; Bing Ma; Farida Ahangari; Yang Zhou; Ruth Halaban; Mario Sznol; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2012-05

3.  C-reactive protein and chitinase 3-like protein 1 as biomarkers of spatial redistribution of retinal blood vessels on digital retinal photography in patients with diabetic retinopathy.

Authors:  Sonja Cekić; Tatjana Cvetković; Ivan Jovanović; Predrag Jovanović; Milica Pesić; Gordana Stanković Babić; Svetislav Milenković; Dijana Risimić
Journal:  Bosn J Basic Med Sci       Date:  2014-08-20       Impact factor: 3.363

Review 4.  Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury.

Authors:  Chun Geun Lee; Carla A Da Silva; Charles S Dela Cruz; Farida Ahangari; Bing Ma; Min-Jong Kang; Chuan-Hua He; Seyedtaghi Takyar; Jack A Elias
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

Review 5.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

6.  Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.

Authors:  Julia Kzhyshkowska; Alexei Gratchev; Sergij Goerdt
Journal:  Biomark Insights       Date:  2007-05-03

7.  Role of breast regression protein-39/YKL-40 in asthma and allergic responses.

Authors:  Chun Geun Lee; Jack A Elias
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

8.  Macrophage chitinase 1 stratifies chronic obstructive lung disease.

Authors:  Eugene Agapov; John T Battaile; Rose Tidwell; Ramsey Hachem; G Alexander Patterson; Richard A Pierce; Jeffrey J Atkinson; Michael J Holtzman
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-02       Impact factor: 6.914

9.  YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.

Authors:  Camilla Noelle Rathcke; Frederik Persson; Lise Tarnow; Peter Rossing; Henrik Vestergaard
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

Review 10.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.